Related Experiment Video
Updated: Jul 11, 2025
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
A Review of Clinical Trials of Cancer and Its Treatment as a Vaccine
Chandani Chandarana1, Anuradha Tiwari1
1Department of Quality Assurance, SSR College of Pharmacy, Sayli Road, Silvassa, U.T of Dadra Nagar and Haveli- 396230, India.
Background:
Cancer and infectious diseases are one of the greatest challenges of modern medicine. An unhealthy lifestyle, poor drug use, or drug misuse contribute to the rise in morbidity and mortality brought on by these illnesses. The inadequacies of the medications now being used to treat these disorders, along with the growing issue of drug resistance, have compelled researchers to look for novel compounds with therapeutic promise. The number of infections and diseases has significantly abated due to vaccine development and use over time, which is described in detail. Several novel vaccines can now be produced by manipulating Deoxyribonucleic acid (DNA), Ribonucleic acid (RNA), Messenger Ribonucleic acid (mRNA), proteins, viral vector Recombinant, and other molecules due to advances in genetic engineering and our understanding of the immune defense.
Objective:
The main topic of discussion is cancer-based vaccinations, which were developed less than a decade ago but have already been used to treat a wide range of both life-threatening and deadly diseases. It contains clinical studies for cancer vaccines against kidney, liver, prostate, cervix, and certain RNA-based cancer vaccines against breast and bladder cancer.
Results:
Numerous studies using various DNA and RNA-based methods have been conducted on the basis of cancer, with 9-10 diseases related to DNA and 8-9 diseases associated with RNA. Some of these studies have been completed, while others have been eliminated due to a lack of research; further studies are ongoing regarding the same.
Conclusion:
This brief discussion of vaccines and their varieties with examples also discusses vaccine clinical trials in relation to cancer diseases in this DNA and RNA-based cancer vaccine that has had successful clinical trials like the cervical cancer drug VGX-3100, the kidney cancer drug Pembrolizumab, MGN-1601, the prostate cancer drug pTVG-HP with rhGM-CSF, the melanoma cancer drug proteasome siRNA, and the lung cancer drug FRAME-001.
Insights
Advancements in genetic engineering enable novel cancer vaccines using DNA and RNA. Clinical trials show promise for treating various cancers, including cervical, kidney, and prostate, addressing limitations of current therapies.
Area of Science:
- Oncology and Immunology
- Biotechnology and Genetic Engineering
Background:
- Cancer and infectious diseases pose significant global health challenges, exacerbated by lifestyle factors and antimicrobial resistance.
- Current treatment limitations and resistance necessitate the development of novel therapeutic compounds.
- Vaccine development, leveraging genetic engineering and understanding of immune defense, has historically reduced disease burden.
Purpose of the Study:
- To discuss the development and clinical application of cancer vaccines, particularly those utilizing DNA and RNA technologies.
- To review clinical studies and outcomes for various cancer vaccines targeting kidney, liver, prostate, cervix, breast, and bladder cancers.
Main Methods:
- Exploration of Deoxyribonucleic acid (DNA), Ribonucleic acid (RNA), and Messenger Ribonucleic acid (mRNA) based vaccine platforms.
- Analysis of genetic engineering techniques for novel vaccine production, including recombinant proteins and viral vectors.
- Review of ongoing and completed clinical studies for DNA- and RNA-based cancer vaccines.
Main Results:
- Multiple DNA- and RNA-based cancer vaccine studies have been conducted, targeting numerous cancer types.
- Some studies have concluded successfully, while others were discontinued due to insufficient research; ongoing research continues.
- Successful clinical trials have been reported for vaccines against cervical, kidney, prostate, melanoma, and lung cancers.
Conclusions:
- Cancer vaccines, particularly DNA- and RNA-based, represent a significant advancement in oncology.
- Clinical trials demonstrate the potential of these novel vaccines in treating diverse and life-threatening cancers.
- Ongoing research and development are crucial for expanding the efficacy and application of cancer vaccines.
More Related Videos
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:21Cancer Survival Analysis